The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 1
  • Lonngren, Thomas
    Consultant born in December 1950
    Individual (2 offsprings)
    Officer
    2010-11-10 ~ dissolved
    OF - Director → CIF 0
    Thomas Lonngren
    Born in December 1950
    Individual (2 offsprings)
    Person with significant control
    2016-04-06 ~ dissolved
    PE - Ownership of shares – 75% or moreCIF 0
Ceased 1
  • Cowan, Graham Michael
    Company Director born in June 1943
    Individual (112 offsprings)
    Officer
    2010-11-02 ~ 2010-11-02
    OF - Director → CIF 0
parent relation
Company in focus

PHARMA EXECUTIVE CONSULTING LIMITED

Standard Industrial Classification
82990 - Other Business Support Service Activities N.e.c.
Brief company account
Please be reminded the displayed account data is older than 4 years hence might not reflect current company status.
Other Investments Other Than Loans
Non-current
144,119 GBP2017-11-30
Fixed Assets - Investments
144,119 GBP2017-11-30
Debtors
107,216 GBP2017-11-30
Cash at bank and in hand
100 GBP2018-11-30
201,130 GBP2017-11-30
Current Assets
100 GBP2018-11-30
308,346 GBP2017-11-30
Creditors
Amounts falling due within one year
103,570 GBP2017-11-30
Net Current Assets/Liabilities
100 GBP2018-11-30
204,776 GBP2017-11-30
Total Assets Less Current Liabilities
100 GBP2018-11-30
348,895 GBP2017-11-30
Net Assets/Liabilities
100 GBP2018-11-30
348,895 GBP2017-11-30
Equity
Called up share capital
100 GBP2018-11-30
100 GBP2017-11-30
Retained earnings (accumulated losses)
348,795 GBP2017-11-30
Equity
100 GBP2018-11-30
348,895 GBP2017-11-30
Average Number of Employees
12017-12-01 ~ 2018-11-30
12016-12-01 ~ 2017-11-30
Property, Plant & Equipment - Gross Cost
10,897 GBP2018-11-30
Property, Plant & Equipment - Accumulated Depreciation & Impairment
10,897 GBP2018-11-30
Amounts invested in assets
Cost valuation, Non-current
144,119 GBP2017-11-30
Non-current
144,119 GBP2017-11-30
Trade Debtors/Trade Receivables
1,219 GBP2017-11-30
Other Debtors
105,997 GBP2017-11-30
Corporation Tax Payable
Amounts falling due within one year
56,171 GBP2017-11-30
Other Taxation & Social Security Payable
Amounts falling due within one year
7,617 GBP2017-11-30
Other Creditors
Amounts falling due within one year
39,782 GBP2017-11-30

  • PHARMA EXECUTIVE CONSULTING LIMITED
    Info
    Registered number 07426392
    Lynton House, 7-12 Tavistock Square, London, London WC1H 9BQ
    Private Limited Company incorporated on 2010-11-02 and dissolved on 2019-05-28 (8 years 6 months). The company status is Dissolved.
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.
© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.